| F |
|
F VIII:C, Ristocetin-cofactor and von Willebrand factor in children with venous thrombosis or cerebral infarction
|
| Becker S., Heller C., Rusicke E., Aygören-Pürsün E., Klarmann D., Biller R., Klingebiel T., Kreuz W. |
| |
|
Factor II 20210 G-A but not Factor V Arg506Gln gene polymorphism is associated with peripheral arterial disease in a case-control study
|
| Reny J. L., Alhenc-Gelas M., Fontana P., Bissery A., Julia P., Fiessinger J. N., Aiach M., Emmerich J. |
| |
|
Factor IX gene deletions are a frequent cause of hemophilia B in India
|
| Jayandharan G., Shaji R. V., Chandy M., Srivastava A. |
| |
|
Factor IXa/factor VIIIa-dependent pathway is responsible for the growth of clot away from the fibroblast monolayer surface
|
| Ovanesov M., Saenko E. L., Ananyeva N. M., Ataullakhanov F. I. |
| |
|
Factor V C2 domain contains major binding site for thrombin
|
| Suzuki H., Shima M., Tanaka I., Nogami K., Sakurai Y., Nishiya K., Takeyama M., Tatsumi K., Yoshioka A. |
| |
|
Factor V endocytosed and retained by megakaryocytes is specifically proteolytically processed by an intracellular protease to form the platelet-derived factor V pool
|
| Bouchard B. A., Thanassi N. M., Tracy P. B. |
| |
|
Factor V Gly2112Asp, a C2-domain variant, is associated with severe deficiency and a bleeding tendency
|
| Olds R., Simioni P., Thompson E., Morgan T., Girolami A., Lane D. A. |
| |
|
Factor V Leiden and blood coagulation at the site of microvascular injury in coumadin treated patients and healthy control
|
| Brzezinska-Kolarz B., Undas A., Sydor W. J., Dziedzina S., Flak A., Musial J. |
| |
|
Factor V Leiden mutation (FV:Q506): A new functional screening assay with 100% specificity and sensitivity
|
| Wilmer M., Stocker C., Piccapietra B., Böck M., Bombeli T. |
| |
|
Factor V Leiden, prothrombin G20210A, and MTHFR C677T gene mutations in patients with primary anti-phospholipid syndrome and cerebrovascular disorder
|
| Kalashnikova L., Patrusheva N., Patrushev L., Kovalenko T., Dobrynina L., Alexandrova E., Nassonov E. |
| |
|
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized
|
| Steen M., Miteva M., Villoutreix B. O., Yamazaki T., Dahlba B. |
| |
|
Factor VII activating protease is an inhibitor of platelet derived growth factor-BB-mediated migratory and mitogenic activities on vascular cells
|
| Kanse S., Kannemeier C., Roemisch J., Preissner K. T. |
| |
|
Factor VII deficiency and stroke: case report
|
| Villaça P. R., D'Amico E. A., Bassitt R. P., Oliveira V., Rocha T. R. F., Chamone D. A. F. |
| |
|
Factor VII deficiency associated with severe hemophilia A
|
| Lombardi A., Cabrio L., Sartori M. T., Zanon E., Granzotto M., Vianello F., Navaglia F., Girolami A. |
| |
|
Factor VII levels, coronary artery disease, and MI
|
| Dym R. J., Kaplan R. C., Monrad E. S., Travin M. I., Freeman R., Billett H. |
| |
|
Factor VII Padua: diagnosis based on differential laboratory tests
|
| Bruty S., Royle D. E., Lavender F. L., O'Shaughnessy D. F. |
| |
|
Factor VII plasma levels and the F7 structural gene: complete dissection of a human quantitative trait locus
|
| Soria J. M., Almasy L., Souto J. C., Sabater-Lleal M., Martinez-Sanchez E., Martinez-Marchan E., Fontcuberta J., Blangero J. |
| |
|
Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis
|
| Bozzini C., Corrocher R., Girelli D., Bozzini C., Ferraresi P., Martinelli N., Olivieri O., Friso S., Villa G., Pizzolo F., Manzato F., Bernardi F. |
| |
|
Factor VIIa directly promotes thrombin burst in the presence of negatively charged phospholipids and factor Va
|
| Arai M., Imai T., Takayama T., Takahashi K. |
| |
|
Factor VIII – factor IX interactions probed by chimeric factor VIII/V variants: complex assembly and cofactor function involve different residues within the A3 domain region 1803–1818
|
| Van Stempvoort G., Fribourg C., Celie P. H. N., Lenting P. J., Mertens K. |
| |
|
Factor VIII activity and blood coagulation in patients on long-term oral anticoagulation
|
| Brzezinska-Kolarz B., Undas A., Sydor W. J., Iwaniec T., Musial J. |
| |
|
Factor VIII expression in liver disease
|
| Hollestelle M. J., Geertzen H. G. M., Straatsburg I. H., Van Gulik T. M., Van Mourik J. A. |
| |
|
Factor VIII inhibitor in a patient with multiple sclerosis and interferon regimen
|
| Makris P., Lachana A., Karali V., Anestakis D., Girtovitis F., Pithara E., Riggos D. |
| |
|
Factor VIII molecular interactions
|
| Mertens K. |
| |
|
Factor VIII pharmacokinetics in young boys with hemophilia: novel measures for prophylaxis dosing
|
| Miller B., Jacobson L. J., Giambartolomei S., Manco-Johnson M. J. |
| |
|
Factor X Cardiff and Factor X Newcastle: Two new FX mutations associated with low activity and antigen levels
|
| Deam S., Uprichard J., Dasani H., Lewis S., Perkins S. J., Hanley J., Dolan G. |
| |
|
Factor Xa is profoundly protected from Antithrombin–arixtra and antithrombin-Lovenox when incorporated into the prothrombinase complex
|
| Brufatto N., Ward A., Nesheim M. E. |
| |
|
Factor XI deficiency in Mestizo Venezuelan population
|
| Ruiz-Sáez A., Arguello A., Boadas A., Feijoo R., Bosch N. |
| |
|
Factor XI dependency of tissue factor-initiated thrombus propagation
|
| Gruber A., Hanson S. R. |
| |
|
Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells
|
| Baird T. R., Walsh P. N. |
| |
|
Factor XI: its role in thrombotic disease of patients with factor V Leiden
|
| Schambeck C., Reibetanz J., Walter U. |
| |
|
Factor XI-activation by thrombin on activated platelets requires both anion binding exosites I and II
|
| Baglia F. A., Yun T. H., Myles T., Navaneetham D., Leung L. L. K., Walsh P.N. |
| |
|
Factor XII-deficiency is a risk factor for ischaemic stroke but not for venous thrombosis in children
|
| Kosch A., Schulte T., Schobeß R., Kurnik K., Heller C., Nowak-Göttl U. |
| |
|
Factor XIII (FXIII) Val34Leu, His95Arg and G30899A polymorphisms and the risk of deep venous thrombosis
|
| Pintão M. C. T., Reges R. V., Lourenço D. M., Morelli V. M., Araújo A. G., Tavella M. H., Zago M. A., Maffei F. H. A., Franco R. F. |
| |
|
Factor XIII and its interactions
|
| Ariens R. |
| |
|
Factor XIII subunit B: a protein A binding protein
|
| Kerényi A., Haramura G., Muszbek L. |
| |
|
Factor XIII Val34Leu polymorphism in pediatric thrombophilia evaluation: is there clinical relevance?
|
| Bidlingmaier C., Spannagl M., Deml M., Kurnik K. |
| |
|
Factor XIII Val34Leu polymorphism in Turkish population
|
| Özbek N., Ataç B., Verdi H., Þahin F. Ý |
| |
|
Factors predicting venous thrombotic complications after superficial–vein thrombosis
|
| Quenet S., Mismetti P., Laporte S., Leizoroviscz A., Epinat M., Decousus H. |
| |
|
Factors that influence the prescribing of low-molecular-weight heparins (LMWHs) in community hospitals: opinions of physicians, clinical pharmacists, and formulary committee members
|
| Nutescu E. A., Park H. Y., Walton S. M., Lewis R. K., Finely J. M., Blackburn J. C., Schumock G. T. |
| |
|
False-positive reaction upon determination of d-dimer by ELISA
|
| Kogan A., Bulargina T. |
| |
|
Familial segregation of venous thromboembolism
|
| Hiet J. A., Phelps M. A., Ward S. A., Slusser J. P., Petterson T. M., De Andrade M. |
| |
|
Family history of thromboembolism does not identify children with thrombophilia – A cross-sectional study
|
| Ruud E., Holmstrøm H., Brosstad F., Wesenberg F. |
| |
|
Fasting homocysteine levels in predicting post methionine loading test results
|
| Pisu G., Fenu L., Cornacchini S., Contu P., Barcellona D., Marongiu F. |
| |
|
Fatal intra cerebral hemorrhage due to severe vitamin K deficiency disclosing cystic fibrosis
|
| Trichet C., Essouri S., Fabre M., Girodon-Boulandet E., Devictor D., Jacquemin E., Dreyfus M. |
| |
|
Fatal pulmonary embolism in medical patients
|
| Peters F., Khan A., Wilmott R., Gardner J., Cohen A. T., Alikhan R. |
| |
|
Favourable course of hemorrhagic complication in early pregnancy of a patient with congenital afibrinogenemia under replacemant therapy
|
| Aygoren-Pursun E., Martinez Saguer I., Rusicke E., Müller W., Becker S., Geka F., Louwen F., Biller R., Klingbiel T., Kreuz W. |
| |
|
Fenoc Study Update
|
| Astermark J. |
| |
|
FGF-2 binds to fibrinogen fragment D1 and prevents degradation to fragment D2
|
| Sahni A., Francis C. W. |
| |
|
FGF-2 but not FGF-1 binds fibrin and supports long-term endothelial cell growth
|
| Sahni A., Altland O. D., Francis C. W. |
| |
|
Fibrin specificity of synergistic combined action of staphylokinase and single-chain urokinase-type plasminogen activator on in vitro clot lysis
|
| Aisina R., Moukhametova L. I., Varfolomeyev S. D. |
| |
|
Fibrinogen – a new tool for gene delivery
|
| Stemberger A., Hacker C., Plank C., Brandt S. |
| |
|
Fibrinogen as predictor of ischemic stroke in patients with nonvalvular atrial fibrillation
|
| Di Lecce V. N., Loffredo L., Fimognari F., Cangemi R., Del Ben M., Alessandri C., Violi F. |
| |
|
Fibrinogen binds to aIIbb3 through a composite site where the known g 400–411 sequence is complemented by residues located in the vicinity of the ‘a’ polymerization site
|
| Lounes K. |
| |
|
Fibrinogen gamma chain splice variant (g') alters fibrin structure and function
|
| Cooper A. V., Standeven K. F., Grant P. J., Ariëns R. A. S. |
| |
|
Fibrinogen gene mutations causing dysfibrinogenemia are associated with variable phenotypes
|
| Winter P. C., O'Neill D. A., Anderson J. A. M. |
| |
|
Fibrinolysis within the procoagulant VX-2 tumor of rabbit lungs in vivo: Anti-angiogenic behavior of fibrin(ogen) degradation products
|
| Hatton M., Southward S. M. R., Legault K. J., Ross B. L., Clarke B. J., Bajzar L., Blajchman M. A., Singh G., Richardson M. |
| |
|
Fibrinolytic activity and response to venous occlusion in activated protein C resistance phenotype
|
| Salviú M., Blanco A. N., Nadal M. V., Gennari L. C., Bermejo E. I., Lazzari M. A. |
| |
|
Fibrinolytic activity of venous endothelium in postphlebitic syndrome
|
| Alexewicz P., Zdziarek J., Adamiec R. |
| |
|
Fibrinopeptide-A generation inhibition by anti-Xa drugs and its correlation with activated clotting time
|
| Demir M., Iqbal O., Schultz C., Ma Q., Hoppensteadt D., Fareed J. |
| |
|
Fibronolytic properties of two-chain urokinase-type plasminogen activator attached to fibrinogen
|
| Moukhametova L., Aisina R. B., Varfolomeyev S. D. |
| |
|
Final results from the Canadian hemophilia dose escalation prophylaxis trial
|
| Feldman B., Rivard G., Israel S., Robinson S., Ali K., Hedden D., Babyn P., Oh P., Einarson T., Mclimont M., Stain A. M., Hilliard P., Blanchette V. S. |
| |
|
FIX Gla Domain: Identification and characterization of residues involved in the phosphatidylethanolamine/phosphatidylserine phospholipid membrane interaction
|
| Schenone M., Rigby A. C., Furie B., Furie B. C. |
| |
|
Flow cytometric evaluation of glycoprotein Iba on the platelet surface in vitro can predict post-transfusion viability of stored platelet concentrates
|
| Leytin V. |
| |
|
Flow cytometry analysis of platelet activation throughout normal gestation and puerperium
|
| Bermejo E., Sanchez-Luceros A., Alberto M. F., Meschengieser S. S., Lazzari M. A. |
| |
|
Flow-induced alterations in endothelial cells: regional genomics of atherosclerosis susceptibility
|
| Davies P. |
| |
|
Fluid shear stress, blood coagulation and epigenome topography of lymphocytes at atherosclerosis: changes of gene expression?
|
| Teplyakov A. I. |
| |
|
Fluorescent conformation sensitive gel electrophoresis (F-CSGE) analysis of the VWF gene: A high throughput, sensitive mutation detection system
|
| Hashemi S. M. B., Hinks J., Marsden L., Peake I. R., Goodeve A. C. |
| |
|
Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (artemis)
|
| Cohen A. T., Gallus A. S., Lassen M. R., Tomkowski W., Turpie A. G. G., Davidson B. L., Cariou R. G., Lensing A. W. A., Egberts J. F. M. |
| |
|
Formation of the catalytically active FVIIa/tissue factor complex leads to enhanced PDGF-BB-stimulated chemotaxis and IL-8 release in monocytes
|
| Johnell M., Siegbahn A. |
| |
|
Foundations of clinical practice - Arterial thromboembolism
|
| Cohen M. |
| |
|
Foundations of clinical practice - Bridging the gap between knowledge and practice
|
| Goldhaber S. |
| |
|
Foundations of clinical practice - Thromboprophylaxis
|
| Kakkar A. |
| |
|
Foundations of clinical practice - Treatment of venous thromboembolism
|
| Prandoni P. |
| |
|
Fractalkine/CX3CL1 production by human aortic smooth muscle cells impairs monocyte procoagulant and inflammatory responses
|
| Ollivier V., Faure S., Tarantino N., Chollet-Martin S., Deterre P., Combadière C., De Prost D. |
| |
|
Frequency and effects of cytochrome P450 2C9 polymorphisms in 61 patients treated by warfarin
|
| Fretigny M., Le Cam-Duchez V., Porte A., Gandelin C., Cailleux N., Levesque H., Borg J.-Y. |
| |
|
Frequency and predictors of vaso-occlusive strokes associated with cardiac surgery in infants and children with congenital heart disease
|
| Domi T., Deveber G., Edgell D., Mccrindle B., Williams W., Macgregor D. |
| |
|
Frequency of biphasic transmittance waveform in the APTT coagulation assay in the patients with underlying diseases of DIC
|
| Wada H., Matsumoto T. M., Sase T. S., Nobori T. N., Shiku H. S., Houdijk W. H. |
| |
|
Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis
|
| Francis J., Drexler A. |
| |
|
Frequency of platelet glycoproteins alpha2807T and GPIbalpha Kozak polymorphisms in central retinal vein occlusion
|
| Regina S., Arsene S., Delahousse B., Maakaroun A., Gruel Y. |
| |
|
Frequency of recurrent thrombosis in patients with antiphospholipid antibodies: a cumulative analysis of prospective trials
|
| Crowther M. |
| |
|
From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer
|
| Levine M. N., Lee A. Y., Kakkar A. K. |
| |
|
Frozen or lyophilized normal plasmas pose a strong bias for reporting PT values
|
| Henckel T., Becker U. |
| |
|
Function of calcium-dependent protein kinase C in platelet aggregation and thrombus formation: Studies using a chemically synthesized TAT-linked peptide blocking the C2 domain of protein kinase C-beta
|
| Heemskerk J., Prinzen L., Feijge M. A. H., Hackeng T. M. |
| |
|
Functional analysis of the prothrombin (PT) G20210A variation
|
| Ceelie H., Spaargaren-Van Riel C. C., Bertina R. M., Vos H. L. |
| |
|
Functional anti-heparin-PF4 antibody-mediated platelet–endothelial cell interactions: modulation of tissue factor activity involved in the HIT pathogenesis
|
| Ahmad S., Amirkhosravi A., Drexler A., Desai H., Amaya M., Siddiqui F. A., Reyes E., Francis J. L. |
| |
|
Functional characterization of a naturally occurring homozygous Gly25Ser mutation in thrombin B chain
|
| Akhavan S., Guillin M. C., Peyvandi F., Mannucci P. M., Bezeaud A. |
| |
|
Functional characterization of recombinant Factor V Liverpool: Ile350Thr, a novel mutation associated with thrombosis
|
| Steen M., Norstrom E., Bolton-Maggs P. H. B., Mumford A., Mcvey J. H., Tuddenham E. G. D., Dahlback B. |
| |
|
Functional characterization of recombinant factor V molecules mimicking the R2-haplotype
|
| Brugge J., Yamazaki T., Tans G., Dahlback B., Rosing J., Nicolaes G. A. F. |
| |
|
Functional consequences of a factor VII gene donor splice site mutation causing a lethal factor VII deficiency: regulation in the splice site selection
|
| Borensztajn K., Sobrier M.-L., Fischer A.-M., Chafa O., Amselem S., Tapon-Bretaudière J. |
| |
|
Functional impairment of protein S in carriers of the prothrombin G20210A mutation
|
| Koenen R.R., Tans G., van Oerle R., Hamulyák K., Rosing J., Hackeng T.M. |
| |
|
Functional modulation of platelet aIIbb3 by its endogenous thiol isomerase activity
|
| Walsh G., Moran N., O'Neill S. |
| |
|
Functional pan-universality of the age-related regulatory elements ASE and AIE, and development of age dimension technology
|
| Kurachi K., Fontaine J.-M., Abe T., Kurachi S. |
| |
|
Functional polymorphisms in the paternally expressed XLas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation resulting in platelet Gs hyperfunction
|
| Freson K., Jaeken J., Wittevrongel C., Thys C., Vermylen J., Hoylaerts M. F., Van Geet C. |
| |
|
Functional properties of recombinant factor Va mutated in a potential calcium-binding site
|
| Sørensen K. W., Nicolaes G. A. F., Villoutreix B. O., Yamazaki T., Tans G., Rosing J., Dahlbäck B. |
| |
|
Functional protein S testing does not exclude protein S deficiency
|
| Rodger M. A., Carrier M., Gervais M., Rock G. |
| |
|
Functional resequencing of the factor IX (f-IX) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-IX activity levels in the GAIT project
|
| Khachidze M., Soria J. M., Almasy L., Souto J. C., Viel K., Blangero J., Fontcuberta J., Howard T. E. |
| |
|
Functional re-sequencing of the factor VIII (f-VIII) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-VIII activity levels in the Gait Project
|
| Viel K., Almasy L., Soria J. M., Khachidze M., Machiah D., Souto J. C., Fontcuberta J., Blangero J., Howard T. E. |
| |
|
Functional significance of single-nucleotide polymorphisms in the glycoprotein VI gene
|
| Onley C. M., Knight C. G., Smethurst P. A., Sundaresan P., Siljander P. R., Joutsi-Korhonen M.-L., Ouwehand W. H., Farndale R. W. |
| |
|
Functional studies of P-selectin polymorphism's associated with coronary diseases
|
| Barek L., Touka M. J., Bardaux S., Cambien F., Mc Gregor J. L. |
| |
|
FV plasma levels and the activated protein C resistance phenotype are modulated by the FV gene Asp79His polymorphism in presence of the FV Leiden mutation
|
| Margaglione M., Bossone A., D'Andrea G., Brancaccio V., Iannaccone L., Cappucci F., Grandone E. |
| |
|
FXa inhibition in general blood coagulation
|
| Becker R. |
| |
|
FXIII promotes endothelial cell migration, proliferation, and inhibits apoptosis
|
| Dardik R., Solomon A., Loscalzo J., Eskaraev R., Bialik A., Dickneite G., Inbal A. |
| |
